Mirion’s second quarter was marked by a negative market reaction despite revenue surpassing Wall Street expectations and adjusted profit meeting consensus. Management attributed the quarter’s top-line growth to broad contributions across all six end markets, with the Medical segment benefiting from shipment timing related to tariffs, while the Nuclear & Safety segment faced some nonrecurring cost pressures. CEO Tom Logan highlighted the company’s continued progress in increasing adjusted free cash flow and optimizing its capital structure, noting, “We demonstrated continued progress on key financial and strategic objectives, most notably increasing adjusted free cash flow generation, stepping up our M&A game and optimizing our capital structure.”
Is now the time to buy MIR? Find out in our full research report (it’s free).
Mirion (MIR) Q2 CY2025 Highlights:
- Revenue: $222.9 million vs analyst estimates of $216.2 million (7.6% year-on-year growth, 3.1% beat)
- Adjusted EPS: $0.11 vs analyst estimates of $0.10 (in line)
- Adjusted EBITDA: $51.2 million vs analyst estimates of $51.52 million (23% margin, 0.6% miss)
- Management raised its full-year Adjusted EPS guidance to $0.50 at the midpoint, a 5.3% increase
- EBITDA guidance for the full year is $228 million at the midpoint, above analyst estimates of $224.2 million
- Operating Margin: 4.6%, up from 1.9% in the same quarter last year
- Market Capitalization: $4.66 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Mirion’s Q2 Earnings Call
- Chris Moore (CJS Securities) asked about the scale and timing of new nuclear opportunities compared to prior years. CEO Thomas D. Logan explained that both the number and urgency of projects are accelerating, citing strategic alliances and policy shifts.
- Chris Moore (CJS Securities) followed up on how the Certrec acquisition aligns with Mirion’s business. Logan emphasized Certrec’s recurring SaaS revenue, strong customer retention, and AI applications for regulatory compliance.
- Joseph Alfred Ritchie (Goldman Sachs) questioned the reliability of growth from the installed nuclear base. Logan described the trend as a generational shift, with underinvestment reversing as operators modernize and extend facility lifetimes.
- Joseph Alfred Ritchie (Goldman Sachs) asked about the $350 million order pipeline and the likelihood of large, lumpy orders. Logan and CFO Brian Schopfer noted some timing shifts but expressed confidence in winning a significant share, especially as the 2026 pipeline builds.
- Rob Mason (Baird) inquired about margin expansion drivers and the impact of procurement. Schopfer highlighted ongoing procurement initiatives, digitalization, and new partnerships, including with Cognizant, supporting both cost control and product development.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will monitor (1) the pace of nuclear power modernization projects and the conversion of the order pipeline into revenue, (2) the scaling and integration of Certrec’s digital regulatory platform within Mirion’s broader portfolio, and (3) ongoing margin expansion efforts through procurement and AI-driven efficiencies. Progress in executing large nuclear and medical contracts, as well as further developments in SMR adoption, will also be critical markers of success.
Mirion currently trades at $22.34, in line with $22.33 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
